Vertex Pharmaceuticals Incorpor (VRTX)

Vertex Pharmaceuticals Incorpor records an AlphaScore of 77/100 within healthcare. Essential metrics include an exceptional gross margin of 86.24% and a net margin of 32.94%. A major strength is its solid return on equity (roe) of 21.18%. A potential risk is its forward price-to-earnings (forwardPe) ratio of 25.37.

Written 11/10/2026, 00:23:31 UTC · Snapshot 11/10/2026